From total empiricism to a rational design of metronomic chemotherapy phase I dosing trials

Thomas Lam, John W. Hetherington, John Greenman, Anthony Maraveyas

Research output: Contribution to journalLiterature review

23 Citations (Scopus)

Abstract

'Metronomic chemotherapy' represents a novel anti-angiogenic strategy whereby low-dose chemotherapy is utilized in a continuous fashion in order to target tumor endothelium. There are many potential advantages of this strategy and clinical trials are already underway. However, although the scheduling of metronomic chemotherapy is relatively unequivocal, metronomic dosing principles are at present poorly defined. Arbitrarily, 10-33% of the maximum tolerated dose comprises 'the dose range'. We argue that this is too empirical and propose a set of phase I metronomic chemotherapy dosing strategies based on a principled approach which may help to reduce the problem of empiricism in dosing for metronomic chemotherapy trials.
Original languageEnglish
Pages (from-to)113-121
Number of pages9
JournalAnti-Cancer Drugs
Volume17
Issue number2
DOIs
Publication statusPublished - Feb 2006

Fingerprint

Empiricism
Drug Therapy
Maximum Tolerated Dose
Endothelium
Clinical Trials
Neoplasms

Keywords

  • endothelial growth cells
  • growth factor
  • metastatic colorectal cancer
  • low dose cycophosphamide
  • acquired drug resistance
  • tumor angiogenesis
  • breast cancer
  • cell proliferation
  • stem cells
  • survival
  • therapy

Cite this

From total empiricism to a rational design of metronomic chemotherapy phase I dosing trials. / Lam, Thomas; Hetherington, John W.; Greenman, John; Maraveyas, Anthony.

In: Anti-Cancer Drugs, Vol. 17, No. 2, 02.2006, p. 113-121.

Research output: Contribution to journalLiterature review

Lam, Thomas ; Hetherington, John W. ; Greenman, John ; Maraveyas, Anthony. / From total empiricism to a rational design of metronomic chemotherapy phase I dosing trials. In: Anti-Cancer Drugs. 2006 ; Vol. 17, No. 2. pp. 113-121.
@article{d2d76da89824432cb37c84745270ccda,
title = "From total empiricism to a rational design of metronomic chemotherapy phase I dosing trials",
abstract = "'Metronomic chemotherapy' represents a novel anti-angiogenic strategy whereby low-dose chemotherapy is utilized in a continuous fashion in order to target tumor endothelium. There are many potential advantages of this strategy and clinical trials are already underway. However, although the scheduling of metronomic chemotherapy is relatively unequivocal, metronomic dosing principles are at present poorly defined. Arbitrarily, 10-33{\%} of the maximum tolerated dose comprises 'the dose range'. We argue that this is too empirical and propose a set of phase I metronomic chemotherapy dosing strategies based on a principled approach which may help to reduce the problem of empiricism in dosing for metronomic chemotherapy trials.",
keywords = "endothelial growth cells, growth factor, metastatic colorectal cancer, low dose cycophosphamide, acquired drug resistance, tumor angiogenesis, breast cancer, cell proliferation, stem cells, survival, therapy",
author = "Thomas Lam and Hetherington, {John W.} and John Greenman and Anthony Maraveyas",
year = "2006",
month = "2",
doi = "10.1097/00001813-200602000-00001",
language = "English",
volume = "17",
pages = "113--121",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - From total empiricism to a rational design of metronomic chemotherapy phase I dosing trials

AU - Lam, Thomas

AU - Hetherington, John W.

AU - Greenman, John

AU - Maraveyas, Anthony

PY - 2006/2

Y1 - 2006/2

N2 - 'Metronomic chemotherapy' represents a novel anti-angiogenic strategy whereby low-dose chemotherapy is utilized in a continuous fashion in order to target tumor endothelium. There are many potential advantages of this strategy and clinical trials are already underway. However, although the scheduling of metronomic chemotherapy is relatively unequivocal, metronomic dosing principles are at present poorly defined. Arbitrarily, 10-33% of the maximum tolerated dose comprises 'the dose range'. We argue that this is too empirical and propose a set of phase I metronomic chemotherapy dosing strategies based on a principled approach which may help to reduce the problem of empiricism in dosing for metronomic chemotherapy trials.

AB - 'Metronomic chemotherapy' represents a novel anti-angiogenic strategy whereby low-dose chemotherapy is utilized in a continuous fashion in order to target tumor endothelium. There are many potential advantages of this strategy and clinical trials are already underway. However, although the scheduling of metronomic chemotherapy is relatively unequivocal, metronomic dosing principles are at present poorly defined. Arbitrarily, 10-33% of the maximum tolerated dose comprises 'the dose range'. We argue that this is too empirical and propose a set of phase I metronomic chemotherapy dosing strategies based on a principled approach which may help to reduce the problem of empiricism in dosing for metronomic chemotherapy trials.

KW - endothelial growth cells

KW - growth factor

KW - metastatic colorectal cancer

KW - low dose cycophosphamide

KW - acquired drug resistance

KW - tumor angiogenesis

KW - breast cancer

KW - cell proliferation

KW - stem cells

KW - survival

KW - therapy

U2 - 10.1097/00001813-200602000-00001

DO - 10.1097/00001813-200602000-00001

M3 - Literature review

VL - 17

SP - 113

EP - 121

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 2

ER -